Report cover image

Corneal Endothelial Dystrophy - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 40 Pages
SKU # DEL18679425

Description

Corneal Endothelial Dystrophy - Pipeline Insight, 2024



DelveInsight’s, “Corneal endothelial dystrophy - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Corneal endothelial dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Corneal endothelial dystrophy Understanding

Corneal endothelial dystrophy: Overview

The term “corneal endothelial dystrophy” refers to a group of diseases that are characterized by a slowly progressive endogenous degeneration of corneal endothelium and are at least in part due to genetic predisposition. The corneal endothelial dystrophies are congenital hereditary endothelial dystrophy 1 (CHED1), congenital hereditary endothelial dystrophy 2 (CHED2), posterior polymorphous corneal dystrophy (PPCD) and Fuchs endothelial corneal dystrophy (FECD). In all cases, degeneration of corneal endothelium ultimately leads to severely impaired vision or blindness, but the molecular pathologies remain largely unknown. Recent efforts have shed more light on the molecular mechanisms of these diseases, and the latest genetic findings enforce the idea of a gradual continuum between endothelial dystrophies. Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and frequently results in vision loss. Hallmarks of the disease include loss of corneal endothelial cells and formation of excrescences of Descemet’s membrane.

""Corneal endothelial dystrophy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Corneal endothelial dystrophy pipeline landscape is provided which includes the disease overview and Corneal endothelial dystrophy treatment guidelines. The assessment part of the report embraces, in depth Corneal endothelial dystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Corneal endothelial dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Corneal endothelial dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Corneal endothelial dystrophy.
Corneal endothelial dystrophy Emerging Drugs Chapters

This segment of the Corneal endothelial dystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Corneal endothelial dystrophy Emerging Drugs
  • TTHX1114: Trefoil Therapeutics
TTHX1114 is a proprietary, engineered form of the naturally occurring molecule Fibroblast Growth Factor-1 (FGF-1), which naturally functions to stimulate cell proliferation and migration as well as protect cells from stress and injury. TTHX1114 has been engineered to increase FGF-1’s pharmacodynamic half-life, enabling its use as a pharmaceutical. TTHX1114 has been shown in preclinical studies to stimulate endothelial cell proliferation and migration, and drive regeneration of the corneal endothelial layer. Currently, it is in Phase II stage of development to treat Corneal Endothelial Dystrophy.
  • Netarsudil mesylate: Aerie Pharmaceuticals
Netarsudil mesylate ophthalmic solution has been developed by Aerie Pharmaceuticals, under a licence from Duke University Medical Center, for the reduction of intraocular pressure in open-angle glaucoma, ocular hypertension and for reducing or resolving corneal edema in Fuchs' endothelial dystrophy.

Further product details are provided in the report……..

Corneal endothelial dystrophy: Therapeutic Assessment

This segment of the report provides insights about the different Corneal endothelial dystrophy drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Corneal endothelial dystrophy
There are approx. 4+ key companies which are developing the therapies for Corneal endothelial dystrophy. The companies which have their Corneal endothelial dystrophy drug candidates in the most advanced stage, i.e. phase II include, Trefoil Therapeutics.
  • Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Corneal endothelial dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Corneal endothelial dystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Corneal endothelial dystrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Corneal endothelial dystrophy drugs.

Corneal endothelial dystrophy Report Insights
  • Corneal endothelial dystrophy Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Corneal endothelial dystrophy Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Corneal endothelial dystrophy drugs?
  • How many Corneal endothelial dystrophy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Corneal endothelial dystrophy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Corneal endothelial dystrophy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Corneal endothelial dystrophy and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Trefoil Therapeutics
  • Aerie Pharmaceuticals
  • Kowa Research Institute, Inc.
  • Emmecell
  • Surrozen
Key Products
  • TTHX1114
  • Netarsudil mesylate
  • K-321
  • EO2002

Table of Contents

40 Pages
Introduction
Executive Summary
Corneal endothelial dystrophy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase II/III)
Comparative Analysis
Netarsudil: Price Vision Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TTHX1114: Trefoil Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EO2002: Emmecell
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Corneal endothelial dystrophy Key Companies
Corneal endothelial dystrophy Key Products
Corneal endothelial dystrophy- Unmet Needs
Corneal endothelial dystrophy- Market Drivers and Barriers
Corneal endothelial dystrophy- Future Perspectives and Conclusion
Corneal endothelial dystrophy Analyst Views
Corneal endothelial dystrophy Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us